APLLTD Alembic Pharmaceuticals Q4 FY26 results (Jan–Mar 2026) and concall
Alembic Pharma reported a resilient Q4 FY26 with a 4% YoY revenue increase to ₹1,838 crores and an 8% rise in EBITDA before R&D to ₹455 crores, driven by new U.S. launches and volume-led growth in API and Animal Health. Full-year revenue grew 10% and PAT increased 16% to ₹675 crores. The company is strategically focusing on execution, quality, and portfolio choices, with an outlook for low double-digit consolidated growth in FY27, despite near-term margin drag from its new U.S. branded business, Pivya, and higher R&D investments in complex products.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 9.4%, net profit up 224.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,580 | 1,406 | 1,571 | 1,494 | 1,796 +14% | 1,642 +17% | 1,719 +9% |
| EBITDA | 259 | 180 | 171 | 214 | 303 +17% | 272 +51% | 274 +60% |
| Net profit | 166 | 86 | 75 | 104 | 179 +8% | 114 +33% | 243 +224% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
